SCHEMBL29435984

SCHEMBL29435984

CC(C)(C)OC(=O)NC12CC(NC(=O)COc3ccc(F)c(F)c3)(C1)C2

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ ATF4 P18848 18/20 0.53
▸ DPP8 Q6V1X1 2/20 0.43
▸ DPP9 Q86TI2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29495534 0.91 ATF4 (0.51) ATF4DPP8DPP9
SCHEMBL22656612 0.90 ATF4 (0.65) ATF4
SCHEMBL19569508 0.88 ATF4 (0.67) ATF4
SCHEMBL23332808 0.85 ATF4 (0.76) ATF4
SCHEMBL30026217 0.84 ATF4 (0.56) ATF4
SCHEMBL29684482 0.84 ATF4 (0.56) ATF4
SCHEMBL29495464 0.84 ATF4 (0.59) ATF4
SCHEMBL23358880 0.83 ATF4 (0.60) ATF4
SCHEMBL30075912 0.82 ATF4 (0.61) ATF4
SCHEMBL22669444 0.82 ATF4 (0.80) ATF4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. 2022-12-29 — — US disclosed
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2022-02-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885DPP8 3963/4885DPP9 3761/4885
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885DPP8 3963/4885DPP9 3761/4885
US-20250388595-A1 MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B, COMPOSITIONS AND METHODS EIF2B1, EIF4EBP1, EIF2B3 ATF4 183/4885DPP8 4114/4885DPP9 3216/4885
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 ATF4 187/4885DPP8 3963/4885DPP9 3761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback